Dr Reddy's launches Tadalafil Tablets to treat erectile dysfunction
Dr Reddy's Tadalafil tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size.
New Delhi: Dr Reddy's Laboratories Wednesday announced the launch of Tadalafil tablets, used to treat erectile dysfunction, in the US market. The approved products is a therapeutic equivalent generic version of Cialis(tadalafil) tablets.
Erectile dysfunction can have psychological consequences as it can be tied to relationship difficulties and self-image. A physical cause can be identified in about 80% of cases. These include cardiovascular disease, diabetes mellitus, neurological problems such as following prostatectomy, hypogonadism, and drug side effect
Read Also: Dr Reddys launches B2B Customer Service Portal XCEED
"Dr Reddy's Tadalafil tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size," Dr Reddy's Laboratories said in a BSE filing.
Tadalafil is used to treat the symptoms of two conditions found in men: benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). Tadalafil is also used to treat pulmonary arterial hypertension (PAH).
Quoting IMS Health data, Dr Reddy's Laboratories said the Cialis brand and generic had US sales of about USD 1.7 billion for the most recent 12 months ending in January 2019.
Read Also: USFDA completes audit for Dr Reddys Shreveport plant, no observations issued
Dr Reddy's Lab was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad.
Dr Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at email@example.com Contact no. 011-43720751 To know about our editorial team click here